16 minute read
Oct. 15, 2023
Fenebrutinib: A Reversible, CNS-Active BTK Inhibitor for MS
fenebrutinib
oral BTK inhibitor Ph. III for multiple sclerosis from ATP site-directed compound libraries + optimization Clinical data release, May 16, 2023 Genentech, South San Francisco, CA
Editor:
Loading...
